Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own0.60% Shs Outstand162.32M Perf Week-11.24%
Market Cap12.11B Forward P/E- EPS next Y-1.39 Insider Trans-17.98% Shs Float161.71M Perf Month-14.50%
Income-189.40M PEG- EPS next Q-1.55 Inst Own100.00% Short Float3.53% Perf Quarter-5.27%
Sales924.10M P/S13.11 EPS this Y-17.30% Inst Trans-0.51% Short Ratio4.00 Perf Half Y-29.51%
Book/sh14.18 P/B5.26 EPS next Y54.00% ROA-5.20% Target Price111.95 Perf Year-44.88%
Cash/sh2.81 P/C26.51 EPS next 5Y25.00% ROE-8.10% 52W Range62.12 - 151.75 Perf YTD-28.78%
Dividend- P/FCF- EPS past 5Y-21.30% ROI-4.20% 52W High-50.83% Beta1.02
Dividend %- Quick Ratio1.80 Sales past 5Y18.80% Gross Margin82.40% 52W Low20.11% ATR3.70
Employees2158 Current Ratio2.60 Sales Q/Q16.70% Oper. Margin-13.60% RSI (14)35.57 Volatility5.00% 4.36%
OptionableYes Debt/Eq0.29 EPS Q/Q-23.10% Profit Margin-20.50% Rel Volume1.42 Prev Close77.01
ShortableYes LT Debt/Eq0.29 EarningsJul 28 AMC Payout- Avg Volume1.42M Price74.61
Recom1.80 SMA20-11.64% SMA50-12.65% SMA200-19.79% Volume2,022,979 Change-3.12%
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Sep-01-15Initiated Raymond James Outperform $148
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Jun-18-15Reiterated Deutsche Bank Buy $140 → $156
Jun-18-15Reiterated Canaccord Genuity Buy $115 → $150
Jun-27-16 02:06PM  Alexion Pharmaceuticals: Brexit Be Damned; Citigroup Ups to Buy Citing "Dark Sky Valuation" at Barrons.com
10:29AM  Is Brexit Good for Biotech? Maybe at Barrons.com
07:01AM  Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Jun-24-16 04:15PM  After Brexit, These Biotech Stocks Are Vulnerable To A Mighty Dollar at Barrons.com -7.94%
Jun-20-16 04:36PM  BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL GlobeNewswire
Jun-17-16 12:25PM  BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
11:13AM  Why Traders Are Buzzing About MGM, Apple, and Three Other Companies Today at Insider Monkey
Jun-16-16 05:10PM  BioMarin Stock Stumbles On Trial Halt, But No New Issue
01:42PM  Why BioMarin (BMRN) Stock Is Lower Today
01:03PM  BioMarin: Overreaction? at Barrons.com
Jun-13-16 09:30AM  The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Jun-10-16 01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
08:01AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-09-16 01:40PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : June 9, 2016
Jun-08-16 08:25AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 8, 2016
Jun-07-16 04:43PM  Sarepta Stock Up On New Twist In Muscular-Dystrophy Drug Saga
09:23AM  Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Jun-02-16 09:04PM  In wake of another delay, Duchenne advocates brace for longer wait at bizjournals.com
12:28PM  Biotech: Is the Rally Real? at Barrons.com
11:32AM  Sarepta Stock Tumbles As Hopes For Muscular Dystrophy Drug Dim
Jun-01-16 04:43PM  BioMarin Stock Slides After Muscular-Dystrophy Drug Shelved
10:21AM  Why BioMarin's Bad News is Great for Sarepta at Barrons.com
09:33AM  Stocks to Watch: Salesforce, Michael Kors, Lands' End, Alibaba at The Wall Street Journal
07:49AM  BioMarin Withdraws Kyndrisa Marketing Application in EU
May-31-16 05:30PM  BioMarin to Stop Developing its Duchenne Muscle Disease Drug at Bloomberg
04:05PM  BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe GlobeNewswire
May-26-16 02:35PM  Sarepta: What the Bulls Say at Barrons.com
11:24AM  Ionis Hits 2-Year Low As GlaxoSmithKline Drops Big Trial Plans
10:52AM  Sarepta: We've Seen This Before at Barrons.com
May-25-16 02:52PM  Is the FDAs decision to delay Sarepta drug decision good or bad? Nobody really knows at MarketWatch
02:07PM  Sarepta Investors Get Carried Away at Bloomberg
12:10PM  Sarepta Therapeutics: Not So Fast at Barrons.com
May-24-16 05:10PM  Incyte Guidance on Jakafi Sends Stock High
May-20-16 12:07PM  A Scarcity of Biotech Assets for Buyouts? at Barrons.com
May-19-16 12:16PM  XBI Large-Caps: Why Is BioMarin Inching Higher?
May-18-16 10:20PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : May 19, 2016
May-17-16 08:27AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : May 17, 2016
May-16-16 01:00PM  Mariner Investments Top Healthcare Picks at Insider Monkey
08:00AM  AbSci Appoints Daniel Gold, Ph.D. to Board of Directors PR Newswire
May-09-16 01:50PM  Wave to begin trials next year on 'more efficient' drug for Duchenne at bizjournals.com
May-08-16 09:45AM  4 Major FDA Decisions Expected by June at 24/7 Wall St.
May-06-16 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials
12:36PM  3 Biotech Stocks Buoyed By Potential Blockbuster Drugs
12:36PM  3 Biotech Stocks Buoyed By Potential Blockbuster Drugs at Investor's Business Daily
May-05-16 05:05PM  BioMarin Pharmaceutical Inc.: Solid Earnings, Pipeline Progressing at Motley Fool
09:00AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : May 5, 2016
May-04-16 08:30AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
May-03-16 09:59AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
08:25AM  BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease GlobeNewswire
May-02-16 09:06AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
May-01-16 10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-29-16 01:32PM  BioMarin (BMRN) Reports Narrower-than-Expected Q1 Loss Zacks
03:13AM  Edited Transcript of BMRN earnings conference call or presentation 28-Apr-16 8:30pm GMT Thomson Reuters StreetEvents
Apr-28-16 04:53PM  BioMarin reports 1Q loss AP
04:22PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Announces First Quarter 2016 Financial Results GlobeNewswire
02:35PM  Why Sarepta Therapeutics Inc. Is Up Big Today at Motley Fool
07:07AM  Q1 2016 Biomarin Pharmaceutical Inc Earnings Release - After Market Close CCBN
07:00AM  Sanofi Presses Medivation to Hold Talks After $9.3B Offer at TheStreet
Apr-27-16 08:57AM  Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings? Zacks
08:21AM  Despite Pleas, FDA Panel Shuns Drug at Motley Fool
Apr-26-16 11:50AM  This Rare Childrens Disease Drug Is Pitting Patients Against the FDA at Fortune
10:05AM  4 Biotechs That Will Escape Weak Seasonal Trends for the Sector at 24/7 Wall St.
Apr-25-16 02:42PM  5 Biotech Stocks to Bet on This Earnings Season Zacks
09:39AM  BioMarin (BMRN) Q1 Earnings: Stock Likely to Beat Estimates Zacks
Apr-21-16 04:30PM  BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome) GlobeNewswire
11:06AM  XBIs Large Caps: BioMarin Gives Update on Gene Therapy Study Market Realist
10:35AM  Sarepta: That Really Wasn't Good at Barrons.com
06:00AM  Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals at TheStreet
Apr-20-16 07:26PM  Cramer Remix: The most dangerous stock group at CNBC
06:06PM  XBI Large Caps: BioMarin to Announce Its 1Q16 Results on April 28 Market Realist
04:49PM  [$$] BioMarin: This Earnings Dynamo Is Priced to Buy at Barrons.com
11:11AM  BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide Benzinga
11:05AM  Can BioMarin Make Treating Hemophilia More Affordable? at 24/7 Wall St.
10:37AM  BioMarin Provides Program Update on Vosoritide in Achondroplasia GlobeNewswire
10:27AM  BioMarin Gene Therapy For Hemophilia Scores In Trial; Stock Jumps at Investor's Business Daily
10:07AM  Why BioMarin is Soaring at Barrons.com
08:52AM  BioMarin announces 'encouraging' early-stage hemophilia therapy data at MarketWatch
08:30AM  BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program GlobeNewswire
Apr-18-16 10:21AM  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
08:30AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York GlobeNewswire
08:18AM  Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?
Apr-13-16 03:39PM  3 Biotech Takeover Targets That Could Get Bought Soon at Motley Fool
Apr-12-16 08:30AM  BioMarin to Host First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, April 28 at 4:30pm ET GlobeNewswire
Apr-11-16 10:01AM  3 Ways Pfizer Can Improve Shareholder Value Without Allergan at Motley Fool
Apr-09-16 10:43AM  Why Sarepta Therapeutics Inc. Soared 44% Higher in March at Motley Fool
Apr-08-16 09:08AM  How Could Baxalta Acquisition Become a Catalyst for Shire?
Apr-07-16 04:04PM  How Does Incytes Valuation Compare to Peers?
12:00PM  BioMarin (BMRN) Stock is the 'Chart of the Day' at TheStreet
11:59AM  3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead at Motley Fool
11:30AM  Why Sarepta Therapeutics Surged 20% in Wednesday Trading?
Apr-06-16 01:04AM  Understanding Acthars Big Contribution to Mallinckrodts Top-line +7.61%
Apr-01-16 06:20AM  Sell These 5 Toxic Stocks Now, Before It's Too Late at TheStreet
Mar-29-16 09:44AM  The 5-Minute Guide to BioMarin Pharmaceutical Stock at Motley Fool
07:00AM  Healthcare: Drug Reform Worries Are Overblown at Morningstar
Mar-28-16 11:50AM  BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU
Mar-24-16 03:15PM  Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
08:38AM  BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A at noodls
08:30AM  BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A GlobeNewswire
Mar-23-16 11:15AM  Jefferies Identifies 5 Top Biotech Stocks for Huge Upside at 24/7 Wall St.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Kyndrisa, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 044, BMN 045, and BMN 053 for DMD treatment; cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis; and and BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate for the treatment of hemophilia A. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as alpha-N-acetyglucosaminidase. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAWLIS V BRYANDirectorJun 20Sale82.7755045,52413,860Jun 21 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Option Exercise17.5441,666730,822420,250Jun 20 08:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 16Sale80.5541,6663,356,196378,584Jun 20 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 06Sale89.141,649146,99246,944Jun 08 08:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Option Exercise39.0616,896659,95871,235Jun 02 06:21 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 31Sale89.8820,8411,873,12650,394Jun 02 06:21 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Option Exercise26.4915,000397,350130,914May 31 06:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 26Sale87.8115,0001,317,100115,914May 31 06:52 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 23Sale87.073,769328,18458,644May 25 02:57 PM
BAFFI ROBERTEVP, Technical OperationsMay 18Sale87.055,000435,249130,386May 19 03:53 PM
Davis George EricEVP, General CounselMay 10Sale86.324,658402,07975,540May 10 07:06 PM
Davis George EricEVP, General CounselMay 09Sale84.5510,000845,53280,198May 10 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise12.9960,000779,40020,000May 09 08:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale80.1550,0004,007,4450May 09 08:47 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 03Sale86.0341535,70163,072May 04 04:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Option Exercise12.9936,500474,135432,135May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 02Sale85.0136,5003,102,931395,635May 04 10:11 AM
BIENAIME JEAN JACQUESChief Executive OfficerApr 06Option Exercise14.391,50021,585395,221Apr 07 08:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,50021,585393,721Apr 07 08:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfficerMar 04Sale88.421,255110,97046,882Mar 07 08:45 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale86.124,623398,12049,688Mar 02 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 01Sale84.2810,000842,769340,500Mar 02 08:38 PM
GREY MICHAEL GDirectorFeb 22Option Exercise38.597,500289,42533,750Feb 23 04:41 PM
GREY MICHAEL GDirectorFeb 22Sale80.007,500600,00026,250Feb 23 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 30Sale94.741,00094,74425,758Dec 02 06:58 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Option Exercise39.0620,000781,20048,229Nov 18 04:03 PM
GREY MICHAEL GDirectorNov 16Option Exercise38.597,500289,42533,750Nov 18 04:49 PM
LAWLIS V BRYANDirectorNov 16Option Exercise17.337,500129,97519,350Nov 18 05:10 PM
GREY MICHAEL GDirectorNov 16Sale104.277,500782,05426,250Nov 18 04:49 PM
LAWLIS V BRYANDirectorNov 16Sale104.261,050109,46811,850Nov 18 05:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Sale104.3020,0002,085,91828,229Nov 18 04:03 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 02Sale117.56263,05735,605Nov 06 05:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 15Sale108.241,000108,24126,758Oct 19 01:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 14Sale131.431,000131,43227,758Sep 16 08:09 PM
HERON ELAINE JDirectorSep 08Option Exercise21.5115,000322,65035,625Sep 25 12:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 12Sale134.721,500202,08328,758Aug 13 10:40 AM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Option Exercise63.103,000189,30038,605Jul 22 03:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Sale150.003,000450,00035,605Jul 22 03:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 07Sale139.071,500208,60030,258Jul 09 05:06 PM